Please login to the form below

Not currently logged in
Email:
Password:

cancer vaccine

This page shows the latest cancer vaccine news and features for those working in and with pharma, biotech and healthcare.

CureVac to acquire Frame Cancer Therapeutics in €32m deal

CureVac to acquire Frame Cancer Therapeutics in €32m deal

and validate promising neoantigens for our mRNA cancer vaccine programmes. ... Ronald Plasterk, founder and CEO of Frame Cancer Therapeutics, said: “We [have a] content-driven approach in antigen discovery and validation and CureVac [has] extensive

Latest news

More from news
Approximately 3 fully matching, plus 153 partially matching documents found.

Latest Intelligence

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    You have a broad pipeline of candidates, including therapeutic vaccines, such as your vaccine for prostate cancer in phase 1. ... How big a role do you think therapeutic vaccines will play in future cancer treatment?

  • Pharma deals in August 2015 Pharma deals in August 2015

    This was the fifth deal announced by AstraZeneca/Medimmune in the month under which the company gained access to INO-3112 a cancer vaccine which targets cancers caused by human papilloma ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112

  • Pharma deals in March 2015 Pharma deals in March 2015

    The companies will collaborate to develop three anti-cancer drugs, one Mab from Lilly and a Mab and an additional molecule from Innovent. ... This is what BMS has secured with Bavarian Nordic's cancer vaccine targeting PSA in phase III for treatment of

  • Pharma deals in February 2015 Pharma deals in February 2015

    This month saw the deadline, highlighted in January's Deal Watch, for Valeant to acquire Dendreon, and more specifically the dendritic cell, prostate cancer vaccine Provenge (sipuleucel-T), come and go.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    R&D and. commercialisation. IMA942 tumour-associated peptide cancer vaccine candidates in NSCLC and prostate cancer. ... BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...